tarlatamab

1. 03:47
   x.com

   "WOW! BIG news for our patients with extensive-stage small cell lung cancer!" — @lungoncdoc
2. 03:06
   x.com

   Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing!
3. 01:47
   x.com

   Absolute first: OS +8.4 mo (21.1 vs 12.7), HR 0.42 — tarlatamab + durvalumab as 1L ES-SCLC maintenance. Also: PFS 7.4 vs 1.9; ORR 26.4% vs 4.1%; CRS ~50% mostly G1–2. Standing ovat
4. 01:34
   x.com

   #ESMO26 #Tarlatamab 👇
5. 01:16
   x.com

   In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with #Tarlatamab maintenance therap
6. 00:48
   x.com

   #ESMO26| 🫁Una nueva combinación, la de #tarlatamab y #durvalumab, reduce el riesgo de muerte en un 58% en #cáncer de pulmón microcítico. @my
7. 00:03
   x.com

   #ESMO26 #DeLLphi305 Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalum

1. 23:59
   x.com

   @sands_jacob with Dellphi305 — tarlatamab w durvalumab vs durvalumab for small cell lung cancer — almost doubling of overall survival w manageable CRS & outpatient treatment. S
2. 23:58
   x.com

   🚨🔥@OncoAlert Hot Off The Press.
3. 23:58
   x.com

   🆙#ESMO26 #LCSM Presidential I Discussion🌟
4. 23:50
   x.com

   Tarlatamab + durva significantly improve OS, PFS, and ORR in 1LM ES-SCLC in maintenance setting. Maintenance vs 2L tarlatamab will be discussed and we wait for data in frontline. A
5. 23:47
   x.com

   Congratulations @sands_jacob on excellent presentation of Dephi-305. Impressive results with a deserved standing ovation. #LCSM #ESMO26
6. 23:00
   x.com

   In extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy meaningfully extended survival. @DanaFarber's
7. 22:59
   x.com

   #ESMO26| 🫁Una nueva combinación, la de #tarlatamab y #durvalumab, reduce el riesgo de muerte en un 58% en #cáncer de pulmón microcítico.
8. 22:49
   x.com

   From #ESMO26 & @NEJM
9. 22:43
   x.com

   🚨🔥@OncoAlert Hot off the press.
10. 22:41
    x.com

    #ESMO26 Presidential 1:
11. 22:35
    x.com

    @myESMO #Tarlatamab #sclc #ESMO26 @StephenVLiu @BalazsHalmosMD @OncoAlert
12. 21:18
    x.com

    At #ESMO26, Hina Khan (@BrownMedicine) discusses a real-world analysis of cytokine release syndrome with #tarlatamab in extensive-stage SCLC, how it compares with trial data
13. 19:20
    x.com

    #ESMO26 . AMGEN Y ASTRAZENECA CON ESTOS RESULTADOS ESTABLECEN LA COMBINACIÓN DE TARLATAMAB Y DURVALUMAB COMO UN NUEVO ESTÁNDAR DE TREATMENT MANTENIMIENTO EN PRIMERA LÍNEA (1LM) PAR
14. 19:04
    x.com

    🔥🔥#ESMO26 Top Thoracic Abstracts:
15. 17:17
    x.com

    #Tarlatamab #ESMO26 #SCLC
16. 14:39
    x.com

    #ESMO26 . AMGEN Y ASTRAZENECA CON ESTOS RESULTADOS ESTABLECEN LA COMBINACIÓN DE TARLATAMAB Y DURVALUMAB COMO UN NUEVO ESTÁNDAR DE TREATMENT MANTENIMIENTO EN PRIMERA LÍNEA (1LM) PAR
17. 13:47
    x.com

    #ESMO26 . AMGEN Y ASTRAZENECA CON ESTOS RESULTADOS ESTABLECEN LA COMBINACIÓN DE TARLATAMAB Y DURVALUMAB COMO UN NUEVO ESTÁNDAR DE TREATMENT MANTENIMIENTO EN PRIMERA LÍNEA (1LM) PAR
18. 02:53
    Cancer Cell

    Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab.

    Lung neuroendocrine carcinomas with high DLL3 expression upregulate TPH1 to increase serotonin (5-HT), which induces immunosuppressive tumor-associated macrophages (TAMs) expressing HTR7, weakening CD8+ T cell function and driving resistance to tarlatamab.

1. 22:30
   news.google.com

   ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra - Fierce Biotech
2. 14:12
   x.com

   https://www.cell.com/cancer-cell/abstract/S1535-6108(26)00435-6 #Tarlatamab,.... provides clinical efficacy against (SCLCs), although its efficacy remains limited, .... We show tha

1. 08:00
   cell.comPick

   Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab

   Nomura et al. found that lung neuroendocrine cancer uses tumor-derived serotonin acting through the HTR7 pathway to program immunosuppressive macrophages, mediating resistance to tarlatamab and ICB. This neuroimmune mechanism holds in both SCLC and LCNEC, and points to HTR7 as a potentially druggable therapeutic vulnerability.

Heat now 149·Peak in the comparable set 187 (Oct 25 04:00)·Change over 24h in the comparable set +791%·Participants now 23

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.